[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Shanghai Yidian Pharmaceutical Technology Development Co., Ltd.\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":155},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,6,0,[8,43,64,84,109,131],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":28,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":31,"lastUpdatePostDateStruct":32,"startDateStruct":35,"completionDateStruct":37,"leadSponsor":39,"locationsCount":42},"100624704","phase-2-efficacy-and-safety-of-yd0743-treatment-for-sepsis-associated-ards-100624704",false,"NCT07413094","Efficacy and Safety of YD0743 Treatment for Sepsis-Associated ARDS","A Multicenter, Parallel, Randomized, Placebo-Controlled Phase II Clinical Study to Evaluate the Efficacy and Safety of YD0743 Injection in the Treatment of Sepsis-Associated Acute Respiratory Distress Syndrome","Inclusion Criteria:\n\n* Male or female, aged between 18 and 75 years (inclusive).\n* Diagnosis of sepsis.\n* Diagnosis of Acute Respiratory Distress Syndrome (ARDS) suspected or confirmed to be caused by sepsis.\n* Time from ARDS diagnosis to signing the informed consent form (ICF) does not exceed 48 hours.\n* The subject (or their legally authorized representative) has fully understood the study's purpose, nature, procedures, and potential adverse events, voluntarily agrees to participate, and provides written informed consent.\n\nExclusion Criteria:\n\n* Known allergy or hypersensitivity to the active ingredient or any excipients of the investigational product; or a history of allergic disorders.\n* Expected survival time is less than 48 hours at the time of screening.\n* Sepsis with extensive burns as the primary cause.\n* Currently diagnosed with active malignancy; or malignancy with distant metastasis; or cancer patients with cachexia; or patients with severe organ dysfunction or visceral hemorrhage due to tumor obstruction, space-occupying effect, or compression, for whom surgical intervention is difficult or has not yet been performed.\n* Currently receiving or requiring Extracorporeal Membrane Oxygenation (ECMO) therapy.\n* Presence of chronic severe organ failure or immunodeficiency\u002Fimmunosuppression.\n* Thrombocytopenia at screening, active\u002Funcontrolled bleeding, or patients whom the investigator considers to have a current or prior high risk of bleeding.\n* Diagnosis of neutropenia.\n* Positive for Hepatitis B surface antigen (HBsAg) with HBV-DNA \\> 1000 copies\u002FmL or 200 IU\u002FmL; positive for Hepatitis C virus antibody (HCV-Ab); positive for Human Immunodeficiency Virus antibody (HIV-Ab); or positive for Treponema pallidum antibody.\n* Participation in other drug or medical device clinical trials within 3 months prior to this study, or current participation in another clinical trial.\n* Pregnant or breastfeeding women, or women planning to become pregnant within the next 6 months.\n* Patients whose underlying primary disease cannot be effectively treated.\n* Any other condition that, in the opinion of the investigator, makes the subject unsuitable for participation in this study.","ALL","18 Years","75 Years",{"count":20,"type":21},309,"ESTIMATED","INTERVENTIONAL",[24],"PHASE2","The goal of this clinical trial is to learn if YD0743 works to treat sepsis-associated acute respiratory distress syndrome (ARDS) in adult patients admitted to the Intensive Care Unit. It will also learn about the safety of drug YD0743. The main questions it aims to answer are:\n\nDoes YD0743 injection shorten the ventilator-using days in sepsis-associated ARDS patients? What medical problems do participants have when accepting YD0743 treatment?\n\nResearchers will compare YD0743 to a placebo (a look-alike substance that contains no active drug) to see if YD0743 works to treat sepsis-associated ARDS.\n\nParticipants will:\n\nAccepting YD0743 injection at least for 7 days. Visit the clinic in person at the Day 28 to receive the follow-up check (D1 is defined as the first day starting the YD0743 or placebo treatment) .",[27],"Sepsis",[29],"Acute respiratory distress syndrome","RECRUITING","2026-02-09",{"date":33,"type":34},"2026-02-17","ACTUAL",{"date":36,"type":34},"2026-02-02",{"date":38,"type":21},"2026-12",{"name":40,"class":41},"Shanghai Yidian Pharmaceutical Technology Development Co., Ltd.","INDUSTRY",1,{"id":44,"slug":45,"hasResults":11,"nctId":46,"briefTitle":47,"officialTitle":48,"acronym":4,"eligibilityCriteria":49,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":50,"targetDuration":4,"studyType":22,"phases":52,"briefSummary":53,"conditions":54,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":56,"lastUpdatePostDateStruct":57,"startDateStruct":59,"completionDateStruct":61,"leadSponsor":63,"locationsCount":42},"100616881","phase-2-evaluate-the-safety-and-efficacy-of-hl-1186-tablet-for-postoperative-pain-management-in-abdominal-surgery-100616881","NCT07311369","Evaluate the Safety and Efficacy of HL-1186 Tablet for Postoperative Pain Management in Abdominal Surgery","A Multi-center, Randomized, Double-blind, Placebo-controlled, Parallel-group Phase Ⅱa Study to Evaluate the Safety and Efficacy of HL-1186 Tablets for Postoperative Pain Management in Abdominal Surgery","Inclusion Criteria:\n\n1. 18 years old ≤ age ≤ 75 years old, gender is not limited.\n2. 18 kg\u002Fm2 ≤ Body Mass Index (BMI) ≤ 30kg\u002Fm2.\n3. Scheduled to undergo abdominal surgeries under general anesthesia.\n4. Able to understand the research process and the use of pain scales, and communicate effectively with researchers.\n\nExclusion Criteria:\n\n1. Prior history of surgery at the same site, and this may affect pain perception at the surgical site per investigator's judgments.\n2. Allergy to any component of the investigational product, to perioperative anesthetic\u002Fanalgesic\u002Fantiemetic agents, or to ≥3 substance allergies.\n3. Unstable angina, myocardial infarction, severe arrhythmias (e.g., third-degree atrioventricular block), New York Heart Association (NYHA) class III or higher cardiac function, recurrent asthma, etc., within screen period, and deemed ineligible per investigator's judgments.\n4. High bleeding risk conditions: Congenital bleeding disorders (e.g., hemophilia), platelet function abnormalities (e.g., idiopathic thrombocytopenic purpura, disseminated intravascular coagulation, congenital platelet function abnormalities), active bleeding, etc., and deemed ineligible per investigator's judgments.\n5. For female participants: Pregnant or lactating (within 1 year postpartum).\n6. Participants with childbearing potential planning conception\u002Fsperm\u002Fegg donation within 6 months post-treatment, or unwilling to use effective contraception (abstinence, barrier methods, oral contraceptives, intrauterine device, or sterilization).\n7. Judgment by the investigator that the participant should not enter the study due to other conditions.",{"count":51,"type":21},40,[24],"This is a multiple-center, randomized, double-blind, placebo-controlled study design evaluating the safety, efficacy, and pharmacokinetics (PK) parameter of HL-1186 tablet for postoperative pain management in abdominal surgery.",[55],"Moderate to Severe Acute Postoperative Pain","2025-12-16",{"date":58,"type":34},"2025-12-30",{"date":60,"type":21},"2025-12",{"date":62,"type":21},"2026-03",{"name":40,"class":41},{"id":65,"slug":66,"hasResults":11,"nctId":67,"briefTitle":68,"officialTitle":69,"acronym":4,"eligibilityCriteria":70,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":71,"targetDuration":4,"studyType":22,"phases":73,"briefSummary":74,"conditions":75,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":76,"lastUpdatePostDateStruct":77,"startDateStruct":79,"completionDateStruct":81,"leadSponsor":83,"locationsCount":42},"100604248","phase-2-evaluate-the-safety-and-efficacy-of-hl-1186-tablet-for-moderate-to-severe-acute-pain-after-surgery-100604248","NCT07147049","Evaluate the Safety and Efficacy of HL-1186 Tablet for Moderate to Severe Acute Pain After Surgery","A Phase 2a, Randomized, Double-blind, Placebo-controlled, Parallel Study Evaluating the Safety and Efficacy of HL-1186 Tablet for Moderate to Severe Acute Pain After Surgery","Inclusion Criteria:\n\n1. 18 years old ≤ age ≤ 75 years old, gender is not limited.\n2. 18 kg\u002Fm2 ≤ Body Mass Index (BMI) ≤ 30kg\u002Fm2.\n3. Scheduled to undergo one of the following elective surgeries under general anesthesia: Orthopedic surgery, abdominal surgery, or thoracic surgery.\n4. Able to understand the research process and the use of pain scales, and communicate effectively with researchers.\n5. Participant reported pain of ≥4 on the NRS.\n\nExclusion Criteria:\n\n1. Prior history of surgery at the same site, and this may affect pain perception at the surgical site per investigator's judgments.\n2. Allergy to any component of the investigational product, to perioperative anesthetic\u002Fanalgesic\u002Fantiemetic agents, or to ≥3 substance allergies.\n3. Use of the prohibited medications specified in the protocol within 5 half-lives of the drug (or 7 days if half-life is unknown) prior to randomization, and this may affect pain or scale assessments per investigator's judgments.\n4. QTcF ≥450 ms (using Fridericia correction), unstable angina, myocardial infarction, severe arrhythmias (e.g., third-degree atrioventricular block), New York Heart Association (NYHA) class III or higher cardiac function, recurrent asthma, etc., within screen period, and deemed ineligible per investigator's judgments.\n5. High bleeding risk conditions: Congenital bleeding disorders (e.g., hemophilia), platelet function abnormalities (e.g., idiopathic thrombocytopenic purpura, disseminated intravascular coagulation, congenital platelet function abnormalities), active bleeding, etc., and deemed ineligible per investigator's judgments.\n6. For female participants: Pregnant or lactating (within 1 year postpartum).\n7. Participants with childbearing potential planning conception\u002Fsperm\u002Fegg donation within 6 months post-treatment, or unwilling to use effective contraception (abstinence, barrier methods, oral contraceptives, intrauterine device, or sterilization).\n8. Participants who have participated in other investigational product\u002Fdevice studies within 30 days prior to the screening visit, or are currently enrolled in another study.\n9. Judgment by the investigator that the participant should not enter the study due to other conditions.",{"count":72,"type":21},72,[24],"This is a multiple-center, randomized, double-blind, placebo-controlled study design evaluating the safety, efficacy, and pharmacokinetics (PK) parameter of HL-1186 tablet for moderate to severe acute pain after surgery.",[55],"2025-12-15",{"date":78,"type":34},"2025-12-22",{"date":80,"type":34},"2025-08-08",{"date":82,"type":21},"2026-01",{"name":40,"class":41},{"id":85,"slug":86,"hasResults":11,"nctId":87,"briefTitle":88,"officialTitle":89,"acronym":4,"eligibilityCriteria":90,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":91,"targetDuration":4,"studyType":22,"phases":93,"briefSummary":94,"conditions":95,"keywords":97,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":101,"lastUpdatePostDateStruct":102,"startDateStruct":104,"completionDateStruct":106,"leadSponsor":108,"locationsCount":42},"100606327","phase-2-a-study-to-evaluate-the-efficacy-and-safety-of-htmc0658-tablets-in-the-treatment-of-chronic-rhinosinusitis-without-nasal-polyps-100606327","NCT07174115","A Study to Evaluate the Efficacy and Safety of HTMC0658 Tablets in the Treatment of Chronic Rhinosinusitis Without Nasal Polyps","A Phase IIa Clinical Study to Evaluate the Efficacy and Safety of HTMC0658 Tablets in the Treatment of Chronic Rhinosinusitis Without Nasal Polyps","Inclusion Criteria:\n\n1. Subjects aged between 18 and 75 years, inclusive, of either sex.\n2. Body Mass Index (BMI) calculated as weight in kilograms divided by the square of height in meters (kg\u002Fm²), with a BMI of at least 18.5.\n3. Subjects must meet the diagnostic criteria for chronic rhinosinusitis as defined in the \"Chinese Chronic Rhinosinusitis Diagnosis and Treatment Guidelines (2024),\" with a disease duration exceeding 12 weeks.\n4. During the screening period, nasal endoscopy must reveal bilateral pathological changes in the nasal mucosa, such as edema and purulent discharge, or a CT scan must show bilateral sinus involvement.\n5. During the screening period, a CT scan must demonstrate bilateral sinus involvement, with at least one sinus on each side scoring ≥ 1 point on the Lund-MacKay (LMK) scale.\n6. During the screening period, the Nasal Congestion Score (NCS) must be ≥ 2 points.\n7. During the screening period, the Composite Symptom Score (CSS) for nasal congestion, rhinorrhea, and facial pain\u002Fpressure must be ≥ 5 points.\n8. During the screening period, the Sino-Nasal Outcome Test-22 (SNOT-22) total score must be ≥ 20 points.\n9. Subjects must have been on a stable daily dose of mometasone furoate nasal spray (MFNS) for at least 4 weeks prior to enrollment.\n10. Subjects with asthma or chronic obstructive pulmonary disease (COPD) must have had stable conditions without exacerbations in the 3 months prior to screening (e.g., no emergency room visits, hospitalizations, or systemic corticosteroid use). The use of inhaled corticosteroids must have been at a stable dose, with continuous use for at least 3 months prior to screening, and planned continuation throughout the study period.\n11. Subjects must fully understand the purpose, nature, methodology, and potential adverse events of the trial, voluntarily participate in the trial, and provide written informed consent, or have an authorized legal representative provide informed consent.\n\nExclusion Criteria:\n\n1. Presence of nasal polyps confirmed by nasal endoscopy during the screening period, or a history of nasal polyps.\n2. Requirement for systemic corticosteroids as maintenance therapy during the screening period.\n3. Diagnosis of cystic fibrosis (CF) or primary ciliary dyskinesia.\n4. Undergone nasal surgery within 4 weeks prior to screening, or scheduled for sinus surgery during the study period.\n5. Presence of significant craniofacial structural abnormalities or severe nasal septal deviation.\n6. Radiological suspicion or confirmed diagnosis of invasive fungal rhinosinusitis, odontogenic sinusitis, osteoma, or nasal tumor.\n7. Presence of a disease or comorbidity that would interfere with the assessment of the primary efficacy endpoints (e.g., subjects with seasonal allergic rhinitis whose symptoms coincide with the study treatment period; subjects with moderate to severe atopic dermatitis requiring treatment with potent topical corticosteroids, topical calcineurin inhibitors, or biologics; subjects with acute upper respiratory tract infection that, in the investigator's judgment, would affect nasal symptom scoring).\n8. Presence of an acute infection requiring antibiotic treatment within 4 weeks prior to screening.\n9. Inflammatory or autoimmune diseases requiring systemic biologic therapy or immunosuppressive agents (including but not limited to immunodeficiency diseases).\n10. Known allergy or intolerance to any component of the investigational medicinal product or background therapy.\n11. Subjects with a past or current diagnosis of periodontitis or palmoplantar keratoderma due to functional deficiency of dipeptidyl peptidase 1 (DPP1), or the presence of the following at screening:a. Subjects with current signs of gingivitis\u002Fperiodontitis.b. Subjects with a history of palmoplantar keratoderma or erythema.\n12. Receipt of drugs that may cause skin hyperkeratosis (e.g., tumor necrosis factor-α antagonists) within 4 weeks prior to screening.\n13. Patients who have used strong CYP3A4 or CYP2D6 inhibitors or inducers within 14 days prior to the first administration of the investigational medicinal product.\n14. Subjects with elevated liver function test results during the screening period and currently requiring treatment for liver disease. Elevated liver function tests are defined as: aspartate aminotransferase (AST) or alanine aminotransferase (ALT) \\> 2.0 × upper limit of normal (ULN), or total bilirubin (TBIL) \\> 1.5 × ULN.\n15. Subjects with positive test results for hepatitis B surface antigen, hepatitis C virus antibody, human immunodeficiency virus antibody, and\u002For syphilis serology during the screening period.\n16. Current smokers (defined as adults who have smoked at least 100 cigarettes in their lifetime and are currently smoking) or those who cannot abstain from smoking during the trial.\n17. Subjects who have participated in other drug or medical device trials within 3 months prior to the start of this trial or are currently enrolled in another clinical trial.\n18. Male subjects who plan to donate sperm or have a fathering plan from the start of dosing until 90 days after the last dose and are unwilling to use effective non-pharmacological contraceptive measures.\n19. Female subjects who plan to donate oocytes or have a pregnancy plan from the start of dosing until 30 days after the last dose and are unwilling to use effective non-pharmacological contraceptive measures.\n20. Pregnant or breastfeeding women.\n21. Subjects whom the investigator deems unsuitable for participation in this study for any reason.",{"count":92,"type":21},30,[24],"The purpose of this clinical trial is to assess the efficacy and safety of HTMC0658 tablets in treating subjects with chronic rhinosinusitis without nasal polyps (CRSsNP).",[96],"Chronic Sinusitis Without Nasal Polyps",[98,99,100],"chronic sinusitis without nasal polyps","Dipeptidyl peptidase 1","neutrophil-related inflammatory","2025-09-15",{"date":103,"type":34},"2025-09-19",{"date":105,"type":34},"2025-08-18",{"date":107,"type":21},"2026-06",{"name":40,"class":41},{"id":110,"slug":111,"hasResults":11,"nctId":112,"briefTitle":113,"officialTitle":114,"acronym":4,"eligibilityCriteria":115,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":116,"targetDuration":4,"studyType":22,"phases":118,"briefSummary":119,"conditions":120,"keywords":4,"overallStatus":122,"whyStopped":4,"lastUpdateSubmitDate":123,"lastUpdatePostDateStruct":124,"startDateStruct":126,"completionDateStruct":128,"leadSponsor":130,"locationsCount":4},"100605186","phase-2-evaluate-the-efficacy-and-safety-of-hl-1186-in-patients-with-diabetic-peripheral-neuropathic-pain-100605186","NCT07159243","Evaluate the Efficacy and Safety of HL-1186 in Patients With Diabetic Peripheral Neuropathic Pain","A Phase 2, Multicenter, Randomized, Double-blind, Placebo-controlled Parallel-designed Clinical Study to Evaluate the Efficacy and Safety of HL-1186 in Patients With Diabetic Peripheral Neuropathic Pain","Inclusion Criteria:\n\n1. Aged between 18 and 75 years old (inclusive), regardless of gender.\n2. With Type 1 or Type 2 diabetes mellitus, with a diagnosis of DPNP for at least 6 months.\n3. Screening period: ADPS ranging from 4 to 9 points, and Visual Analog Scale (VAS) scores of 40mm - 90mm in two different days.\n4. The hypoglycemic regimen has been stable for at least 4 weeks before enrollment, and the glycated hemoglobin (HbA1c) during the screening period is ≤ 9%.\n5. Participants fully understand the purpose, characteristics, methods of the trial and possible adverse events, voluntarily participate in the trial and sign the informed consent form.\n\nExclusion Criteria:\n\n1. Participants with any pain other than DPNP, or with other diseases that the investigator deems may affect the evaluation of DPNP.\n2. Participants who are allergic to the active ingredients or excipients of HL-1186, HL-1186 placebo, or paracetamol tablets, or who have an allergic constitution, or have a history of allergies to ≥ 3 substances.\n3. Participants who have used drugs that may damage nerves (such as tumor chemotherapy drugs) after being diagnosed with DPNP.\n4. Participants who used any prohibited drugs within 2 weeks before screening (or within 5 half-lives after the last use of such prohibited drugs at the time of screening, whichever is longer).\n5. Participants who had acute diabetic complications within 6 months before screening, such as diabetic ketoacidosis, hyperglycemic hyperosmolar state, lactic acidosis, acute severe hypoglycemia, etc., or had lower limb amputation (except toe amputation) at the time of screening.\n6. Participants with clinically significant abnormalities in the 12-lead electrocardiogram (ECG) during the screening period (such as QTcF ≥ 450ms), or with severe cardiopulmonary diseases that the investigator deems inappropriate for inclusion, such as unstable angina pectoris, myocardial infarction, severe arrhythmias requiring treatment (such as grade Ⅲ atrioventricular block), NYHA cardiac function class ≥ Ⅲ, poorly controlled hypertension (systolic blood pressure \\> 160 mmHg or diastolic blood pressure \\> 100 mmHg), recurrent asthma, etc.\n7. Participants with neuropsychiatric system diseases that the investigator deems may affect the participant's evaluation of DPNP or scale evaluation, such as depression, anxiety, epilepsy, recurrent dizziness, memory and cognitive impairment, a history of suicide attempts or suicidal tendencies, etc.\n8. Participants with a history of malignant tumors within 2 years before screening (except for participants with basal cell carcinoma, squamous cell carcinoma, and stage 0 cervical carcinoma in situ that have been confirmed cured by the investigator).\n9. Participants with clinically significant and unstable diseases of the nervous system, mental system, ophthalmology, hepatobiliary system, respiratory system, hematological system, or cardiovascular system within 1 year before screening, and the investigator assesses that such diseases may endanger the participant's safety during the trial, restrict the participant from completing the study procedures, or affect the research purpose.\n10. Participants with positive human immunodeficiency virus antibody, positive syphilis serological test, positive hepatitis B virus surface antigen with hepatitis B virus DNA \\> ULN, or positive hepatitis C virus antibody with hepatitis C virus RNA \\> ULN.\n11. Participants with a history of alcoholism or drug abuse within 2 years before screening.\n12. Female participants who are pregnant, breastfeeding (within 1 year after delivery), or with a positive pregnancy test.\n13. Participants of childbearing potential who have plans to conceive, freeze or donate sperm\u002Feggs from the time of signing the informed consent form until 6 months after the last dose, or who refuse to adopt effective contraceptive measures (complete abstinence, barrier methods, contraceptives, intrauterine devices, or having undergone sterilization surgery).\n14. Participants who have participated in other drug or medical device trials within 3 months before screening or are currently participating in other clinical trials.\n15. Participants deemed by the investigator to be unsuitable for participating in this study for any reason.",{"count":117,"type":21},180,[24],"This is a multi-center, randomized, double-blind, placebo-controlled study design evaluating the safety, efficacy, and PK parameter of HL-1186 tablet for diabetic peripheral neuropathic pain.",[121],"Diabetic Peripheral Neuropathic Pain","NOT_YET_RECRUITING","2025-09-03",{"date":125,"type":34},"2025-09-08",{"date":127,"type":21},"2025-09",{"date":129,"type":21},"2026-10",{"name":40,"class":41},{"id":132,"slug":133,"hasResults":11,"nctId":134,"briefTitle":135,"officialTitle":136,"acronym":4,"eligibilityCriteria":137,"healthyVolunteers":138,"sex":16,"minAge":17,"maxAge":139,"enrollmentInfo":140,"targetDuration":4,"studyType":22,"phases":142,"briefSummary":144,"conditions":145,"keywords":4,"overallStatus":30,"whyStopped":4,"lastUpdateSubmitDate":147,"lastUpdatePostDateStruct":148,"startDateStruct":150,"completionDateStruct":152,"leadSponsor":154,"locationsCount":42},"100586201","phase-1-assess-the-safety-tolerability-and-pharmacokinetics-of-hl-1186-in-healthy-participants-100586201","NCT06912295","Assess the Safety, Tolerability, and Pharmacokinetics of HL-1186 in Healthy Participants","A Phase 1 Study to Assess the Safety, Tolerability, and Pharmacokinetics of Single and Multiple Oral Doses of HL-1186 in Healthy Participants","Inclusion Criteria:\n\n1. Healthy participants, males and females.\n2. Between the ages of 18 and 45 years old (inclusive).\n3. Weighs no less than 50 kg (for males) or 45 kg (for females) and body mass index (BMI) within 19.0 to 26.0 kg\u002Fm2 (inclusive).\n4. During the screening period, vital signs, physical examination, blood routine, blood biochemistry, coagulation function, urine routine, virology examination, chest X-ray, and pregnancy blood test (female) were examined, and the results did not show abnormalities or abnormalities without clinical significance.\n\nExclusion Criteria:\n\n1. Females who are pregnant or breastfeeding; females\u002Fmales who are prepared for having children.\n2. History or presence of neurological, cardiovascular, renal, hepatic, gastrointestinal, respiratory, hematological, endocrine, or osteoarticular disorders, or any laboratory abnormalities that pose a potential danger to constitute a risk when taking the study intervention or interfere with the interpretation of data.\n3. Active infectious diseases which need anti-infection treatment.\n4. Significant surgery within three months and not fully recovered per investigator's judgments.\n5. Significant allergies per investigator's judgments, e.g., food allergies, allergies, or atopic reactions to any components of the investigational drug or placebo, asthma attacks, etc.\n6. Immunosuppressive diseases, e.g., immunodeficiency, etc.",true,"45 Years",{"count":141,"type":21},76,[143],"PHASE1","This single-center, randomized, double-blind, placebo-controlled, two-part study is designed to assess the safety, tolerability and PK of oral HL-1186 Tablet in healthy participants.",[146],"Healthy Participants","2025-08-19",{"date":149,"type":34},"2025-08-24",{"date":151,"type":34},"2025-03-21",{"date":153,"type":21},"2025-10-09",{"name":40,"class":41},""]